Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients (NCT02544776) | Clinical Trial Compass
CompletedNot Applicable
Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients
60 participantsStarted 2015-01
Plain-language summary
On the basis of the current study, amlodipine seems to be a promising drug on improving uterine, ovarian blood flow, size of pre-ovulatory follicle, midluteal progesterone level and pregnancy outcome in patients with pco.
Who can participate
Age range20 Years – 35 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Demographic features including females in age of ≥20 \& ≤35, and BMI of ≤39.
* Infertility secondary to polycystic ovary , The choice of polycystic ovary patients will be according to the Rotterdam consensus workshop (Rotterdam, 2004), and the diagnosis of polycystic ovary by ultrasonography will be made according to Adams et al. criteria which are the most often cited (Adams et al., 1985).The Rotterdam criteria as follows:
* Oligo- or anovulation.
* Clinical and/or biochemical signs of hyper androgynism
* The presence of polycystic ovaries on ultrasound scan. Ultrasound findings of enlarged ovaries with multiple small cysts (10-12 or more of 2-9 mm in diameter) scattered around the periphery and highly echogenic stroma
Exclusion Criteria:
* Including other causes of infertility diagnosed during infertility work up.
* Patients refused to participate or to continue study.
* Also, hepatic, cardiac, and hypotensive patients will be excluded from the study.
What they're measuring
1
change in ovarian artery perfusion
Timeframe: day number five and day number 9 of menstrual cycle